These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 31441063)
1. Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis. Dimmitt SB; Martin JH Med J Aust; 2019 Sep; 211(6):284-284.e1. PubMed ID: 31441063 [No Abstract] [Full Text] [Related]
2. Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis. Brieger DB; Weaver J; Kritharides L Med J Aust; 2019 Sep; 211(6):285-285.e1. PubMed ID: 31441055 [No Abstract] [Full Text] [Related]
3. Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis. Brieger D; D'Souza M; Hyun K; Weaver JC; Kritharides L Med J Aust; 2019 Feb; 210(2):80-85. PubMed ID: 30712304 [TBL] [Abstract][Full Text] [Related]
4. Lipid Lowering in Acute Coronary Syndrome: Is Treatment Early Enough? Nicholls SJ; Psaltis PJ JAMA; 2018 Apr; 319(13):1325-1326. PubMed ID: 29525819 [No Abstract] [Full Text] [Related]
5. Acute coronary syndrome and lipid-lowering therapy in a realistic diagnostic-therapeutic care pathway. Sampietro T; Sbrana F; Dal Pino B; Bigazzi F; Palmieri C; Berti S Pharmacol Res; 2021 Sep; 171():105763. PubMed ID: 34252553 [No Abstract] [Full Text] [Related]
6. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). Javed U; Deedwania PC; Bhatt DL; Cannon CP; Dai D; Hernandez AF; Peterson ED; Fonarow GC Am Heart J; 2010 Dec; 160(6):1130-6, 1136.e1-3. PubMed ID: 21146668 [TBL] [Abstract][Full Text] [Related]
8. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER). Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705 [TBL] [Abstract][Full Text] [Related]
9. Current status of lipid management in acute coronary syndrome. Fujisue K; Tsujita K J Cardiol; 2017 Aug; 70(2):101-106. PubMed ID: 28325524 [TBL] [Abstract][Full Text] [Related]
10. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484 [TBL] [Abstract][Full Text] [Related]
11. Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. Kreisberg RA; Oberman A J Clin Endocrinol Metab; 2002 Feb; 87(2):423-37. PubMed ID: 11836262 [No Abstract] [Full Text] [Related]
12. Treatment strategies for management of serum lipids: lessons learned from lipid metabolism, recent clinical trials, and experience with the HMG CoA reductase inhibitors. Rubenfire M; Coletti AT; Mosca L Prog Cardiovasc Dis; 1998; 41(2):95-116. PubMed ID: 9790412 [TBL] [Abstract][Full Text] [Related]
13. Statins in coronary artery bypass grafting surgery: lipid lowering and beyond. Margaritis M; Antoniades C Expert Rev Cardiovasc Ther; 2012 Jan; 10(1):5-8. PubMed ID: 22149521 [No Abstract] [Full Text] [Related]
14. Trials of lipid-lowering therapy in secondary prevention of coronary heart disease. Olsson AG; Pedersen T; Bergdahl B Curr Opin Lipidol; 1995 Dec; 6(6):369-73. PubMed ID: 8750250 [TBL] [Abstract][Full Text] [Related]
15. [Lipid-lowering therapy of patients suffering from acute coronary syndrome in a Hungarian county hospital in 2015]. Márk L; Nagy M; Dani G; Baranyai C; Borbély M; Katona A; Jambrik Z Orv Hetil; 2018 Mar; 159(12):478-484. PubMed ID: 29552926 [TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the Hellenic Registry of Clinical events and Adherence to Lipid LowerINg therapy In aCUte coronary Syndrome (CALLINICUS-Hellas Registry). Rallidis LS; Tasoulas D; Leventis I; Malkots B; Kladou E; Zapantiotis D; Theofilatos A; Zormpas G; Kalogeras P; Betsis C; Lykoudis A; Tsamoulis D; Kalantzis C; Miliotou A; Daios S; Delakis I; Manolis G; Papathanasiou KA; Vlachopoulos C Hellenic J Cardiol; 2022; 66():84-86. PubMed ID: 35623541 [No Abstract] [Full Text] [Related]
17. Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective. Ara R; Rafia R; Ward SE; Wierzbicki AS; Reynolds TM; Rees A; Pandor A Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):423-33. PubMed ID: 19817526 [TBL] [Abstract][Full Text] [Related]
18. Value of expert opinion in recommending early intensive lipid lowering in patients with ACS. White HD Eur Heart J Acute Cardiovasc Care; 2022 Dec; 11(12):936-938. PubMed ID: 36574352 [No Abstract] [Full Text] [Related]
19. Strategies for implementing lipid-lowering therapy: pharmacy-based approach. Birtcher KK; Bowden C; Ballantyne CM; Huyen M Am J Cardiol; 2000 Feb; 85(3A):30A-35A. PubMed ID: 10695705 [TBL] [Abstract][Full Text] [Related]
20. Timing of intake of lipid lowering drugs: is that of importance? Hanefeld M Klin Wochenschr; 1989 May; 67(9):511-2. PubMed ID: 2733381 [No Abstract] [Full Text] [Related] [Next] [New Search]